Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 8/2016

Open Access 01-08-2016 | Original Article

Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study

Authors: Koichi Takayama, Shinji Atagi, Fumio Imamura, Hiroshi Tanaka, Koichi Minato, Toshiyuki Harada, Nobuyuki Katakami, Takuma Yokoyama, Kozo Yoshimori, Yuichi Takiguchi, Osamu Hataji, Yuichiro Takeda, Keisuke Aoe, Young Hak Kim, Soichiro Yokota, Hiroshi Tabeta, Keisuke Tomii, Yasuo Ohashi, Kenji Eguchi, Koshiro Watanabe

Published in: Supportive Care in Cancer | Issue 8/2016

Login to get access

Abstract

Purpose

Although cancer cachexia is mainly characterized by persistent loss of body weight (BW), usually in response to a malignancy, the pathophysiology of cachexia remains unresolved. To elucidate the relationship between the loss of BW and other related clinical factors, we conducted a nationwide, multi-institutional, prospective, observational study in patients with advanced non-small cell lung cancer (NSCLC).

Methods

Treatment-naïve stage IV NSCLC patients with an Eastern Cooperative Oncology Group performance status (PS) of 0–2 were eligible. BW, handgrip strength (HGS), quality of life (QOL), Karnofsky Performance Scale (KPS), biochemical parameters, and survival were evaluated at baseline and every 4 weeks for 1 year. The relationship between BW loss and other factors was examined by linear regression analysis. Estimated survival curves were drawn by the Kaplan-Meier method and applied by the log-rank test. Clinical factors associated with cancer cachexia were identified through principal component analysis. The generalized estimating equation approach was used to analyze the deterioration of QOL resulting from the progression of cachexia.

Results

A total of 406 patients were analyzed. BW loss was significantly associated with worsening of QOL, HGS, KPS, and biochemical parameters. The incidence of BW loss was observed throughout the study period. Overall survival was significantly shorter in patients as BW loss progressed. BW loss, decrease in HGS, anorexia, and fatigue were identified as core factors of cachexia that contributed to the deterioration of QOL.

Conclusion

BW loss most likely deteriorated QOL and shortened survival in patients with advanced NSCLC and should be closely monitored.
Appendix
Available only for authorised users
Literature
1.
O’Gorman P, McMillan DC, McArdle CS (1999) Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 35:127–129CrossRefPubMed
2.
O’Gorman P, McMillan DC, McArdle CS (2000) Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer 37:36–40CrossRefPubMed
3.
4.
5.
DeWys WD, Begg C, Lavin PT, et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491–497CrossRefPubMed
6.
Ross PJ, Ashley S, Norton A, et al. (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90:1905–1911CrossRefPubMedPubMedCentral
7.
Okuyama T, Wang XS, Akechi T, et al. (2003) Japanese version of the MD Anderson Symptom Inventory: a validation study. J Pain Symptom Manag 26:1093–1104CrossRef
8.
Kurihara M, Shimizu H, Tsuboi K, et al. (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8:355–363CrossRefPubMed
9.
Proctor MJ, Morrison DS, Talwar D, et al. (2011) An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer 104:726–734CrossRefPubMedPubMedCentral
10.
Kim KH (2005) The relation among fit indexes, power, and sample size in structural equation modeling. Struct Equ Model 12:368–390CrossRef
11.
Fearon K, Strasser F, Anker SD, et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489–495CrossRefPubMed
12.
Temel JS, Greer JA, Muzikansky A, et al. (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742CrossRefPubMed
13.
Aapro M, Arends J, Bozzetti F, et al. (2014) Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 25:1492–1499CrossRefPubMed
14.
Prado CM, Baracos VE, McCargar LJ, et al. (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13:3264–3268CrossRefPubMed
15.
Prado CM, Baracos VE, McCargar LJ, et al. (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920–2926CrossRefPubMed
16.
Stene GB, Helbostad JL, Balstad TR, et al. (2013) Effect of physical exercise on muscle mass and strength in cancer patients during treatment—a systematic review. Crit Rev Oncol Hematol 88:573–593CrossRefPubMed
17.
Garcia JM, Boccia RV, Graham CD, et al. (2015) Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomized, placebo-controlled, double-blind trials. Lancet Oncol 16:108–116CrossRefPubMed
18.
Temel JS, Currow DC, Fearon K et al (2015) Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). Abstract 9500. 2015 ASCO Annual Meeting, San Francisco, CA, August 7–8, 2015. J Clin Oncol 33 (suppl; abstr 9500)
Metadata
Title
Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients—Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study
Authors
Koichi Takayama
Shinji Atagi
Fumio Imamura
Hiroshi Tanaka
Koichi Minato
Toshiyuki Harada
Nobuyuki Katakami
Takuma Yokoyama
Kozo Yoshimori
Yuichi Takiguchi
Osamu Hataji
Yuichiro Takeda
Keisuke Aoe
Young Hak Kim
Soichiro Yokota
Hiroshi Tabeta
Keisuke Tomii
Yasuo Ohashi
Kenji Eguchi
Koshiro Watanabe
Publication date
01-08-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3156-8

Other articles of this Issue 8/2016

Supportive Care in Cancer 8/2016 Go to the issue

Letter to the editor

Re: “Prediction of skeletal-related events in patients with non-small cell lung cancer”—use of Spine Instability Neoplastic Score (SINS)

Review Article

The lived experience of fatigue in children and adolescents with cancer: a systematic review

Commentary

From normal response to clinical problem: definition and clinical features of fear of cancer recurrence

Original Article

Preferences for the organization of long-term follow-up in adolescent and young adult cancer survivors

Review Article

Comparison of the FACT-C, EORTC QLQ-CR38, and QLQ-CR29 quality of life questionnaires for patients with colorectal cancer: a literature review

Original Article

Demographic, clinical, psychosocial, and environmental correlates of objectively assessed physical activity among breast cancer survivors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits